Viral vectors are commonly used tools by molecular biologists delivering genetic materials into cells. The specialized molecular mechanisms are evolved by viruses for efficient transport of their genomes inside the cells that are infected by them with the process of transduction.
Viral vectors and plasmid DNA can be applied in gene therapy to treat different diseases such as heart defects, metabolic diseases, cancer, and neurodegenerative disorders. Being based on baculovirus, herpes simplex viruses, adenoviruses, and others, viral vectors are finding greater application in vaccinology and novel drug development. Vectors should be modified to provide safe handling (no production of new virions in a host) and low toxicity (no effect on the physiology of the normal host cell). They should also be stable (no rearrangement of the genome), and for manufacturing, it is important that the viral vector is easily quantified and that it lends itself to large-scale production.
COVID-19 Impact analysis
The COVID-19 epidemic has opened up significant opportunities for market players. For example, in December 2020 and February 2021, multinational pharmaceutical companies such as AstraZeneca and Janssen Pharmaceuticals developed COVID-19 viral vector-based vaccines, respectively. Aside from these firms, several viral vector-based vaccines are now in development. As a result, demand for viral vectors has increased, resulting in increased revenue for viral vector manufacturers due to the COVID-19 pandemic.
Top Impacting Factors
- There is an increase in the need for viral vector and plasmid DNA production due to rise in multiple genetic disorders and various cancers.
- Furthermore, factors such as technological advancements to address challenges posed by traditional vector production methods, surge in the number of clinical studies, and rise in number of gene therapy candidates, combined with their rapid progression through various stages of clinical development propel the demand for viral vector and plasmid DNA manufacturing.
- The expansion of the viral vectors and plasmid DNA manufacturing market is fueled by a rise in funding for gene therapy R&D activities and an increase in public awareness about gene therapy.
- Furthermore, the rise in demand for synthetic genes and the untapped expanding market potential are projected to open up new opportunities for market players during the forecast period.
- However, high expense of gene therapies, as well as the risk of mutagenesis and other barriers to gene therapy limits the market expansion.
Market Trends
New product launches to flourish the market
In 2018, UniQure Biopharma BV sponsored for the trial of AMT-061 in severe or moderately severe Hemophilia B patients, and AMT-061 is a recombinant adeno-associated viral vector.
In March 2021, the U.S. FDA approved ABECMA (idecabtagene vicleucel), a lentivirus-based gene therapy to treat R/R multiple myeloma. With the increasing gene therapy approvals and consequent increase in manufacturing capabilities, the competition in this arena is anticipated to intensify in the near future.
in April 2021, Albumedix extended research collaboration with Cobra Biologics for the upstream and downstream processing of AAV and lentiviral vector. Collaboration is intended for stability enhancement and process optimization.
Key Benefits of the Report
- This study presents the analytical depiction of the Viral Vector and Plasmid DNA along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Viral Vector and Plasmid DNA market share.
- The current market is quantitatively analyzed to highlight the Viral Vector and Plasmid DNA market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed Viral Vector and Plasmid DNA market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Viral Vector and Plasmid DNA Report
- Who are the leading market players active in the Viral Vector and Plasmid DNA market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is "Viral Vector and Plasmid DNA"?
- What is "Viral Vector and Plasmid DNA" Market prediction in the future?
- Who are the leading global players in the "Viral Vector and Plasmid DNA" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Viral Vector and Plasmid DNA" Market report?
Key Market Segments
- By Product Type
- Plasmid DNA
- Viral Vector
- Non Viral Vector
- By Application
- Cancer
- Genetic Disorder
- Others
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- CobraBiologics
- UniQure N.V.
- Merck KGaA
- Novasep
- Cell and Gene Therapy Catapult
- Lonza
- Kaneka Eurogentec, Inc.
- FUJIFILM
- Diosynth Ltd.
- Spark Therapeutics, Inc.